OSE

No price yet

Announcements

Nothing here yet

Daily updates

Nothing here yet

FDA designations

Nothing here yet

News

OSE Immunotherapeutics reports positive topline results from the randomized Phase 2 Combi-TED trial of Tedopi (OSE2101) in metastatic non-small cell lung cancerOct 19, 2026
Veloxis dosed the first patient in the Phase 2 RENGEVITY-201 trial of pegrizeprument (VEL-101) to prevent organ rejection in kidney transplant recipientsSep 10, 2026